April 20, 2018 - By Sarah North

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCF) Corporate Logo

CHUGAI PHARMACEUTICAL CO LTD ORDINARY SH (OTCMKTS:CHGCF) showed an increase of 1.43% in short interest. FINRA published short interest of CHGCF’s total 212,500 shares. Previously was reported up change of 1.43% from 209,500 shares. With Average volume 100, CHGCF’s former position will take 2125 days to restore.

The last price was $50.49.Since April 20, 2017 it’s 0.00% down thus . The stock underperformed the S&P 500 by 11.55%.

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research and development, manufacture, marketing, and distribution of prescription medicines in Japan, Switzerland, and internationally.The firm is valued at $28.82 billion. The company's products for oncology include Avastin, Herceptin, Rituxan, Xeloda, Tarceva, Perjeta, Alecensa, Neutrogin, Kadcyla, Zelboraf, Aloxi, and Akynzeo; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, Bonviva, and Alfarol; renal diseases consist of Mircera, Oxarol, and Epogin; and transplant, immunology, infectious, and other diseases comprise Tamiflu, CellCept, Copegus, Pegasys, and Sigmart.The P/E ratio is 40.65. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.